Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)0.5172
  • Today's Change0.024 / 4.87%
  • Shares traded2.26m
  • 1 Year change-50.74%
  • Beta0.8611
Data delayed at least 15 minutes, as of Dec 06 2016 15:43 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Dec 03, 2016, the consensus forecast amongst 2 polled investment analysts covering CTI BioPharma Corp advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 10, 2016. The previous consensus forecast advised that CTI BioPharma Corp would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy0
Outperform0
Hold1
Underperform1
Sell0

Research reports

Ford Investor Services, Inc.

S&P Capital IQ Quantitative Report

CTI BioPharma
12 pages, 22 Oct 2016
More ▼

Share price forecast

The 2 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 0.375, with a high estimate of 0.75 and a low estimate of 0.00. The median estimate represents a -23.97% decrease from the last price of 0.4932.
High54.6%0.75
Med-22.7%0.375
Low-100.0%0.00

Earnings history & estimates

On Nov 08, 2016, CTI BioPharma Corp reported 3rd quarter 2016 losses of -0.10 per share. This result under-performed the -0.070 loss expectation of the 2 analysts following the company but under-performed last year's 3rd quarter results by 44.44%.
The next earnings announcement is expected on Feb 14, 2017.
Average growth rate-7.54%
CTI BioPharma Corp reported annual 2015 losses of -0.65 per share on Feb 16, 2016.
The next earnings announcement from CTI BioPharma Corp is expected the week of Feb 14, 2017.
Average growth rate+19.02%
More ▼

Revenue history & estimates

CTI BioPharma Corp. had 3rd quarter 2016 revenues of 4.43m. This bettered the 3.95m consensus of the 2 analysts covering the company. This was 359.85% above the prior year's 3rd quarter results.
Average growth rate+294.30%
CTI BioPharma Corp. had revenues for the full year 2015 of 16.12m. This was 73.17% below the prior year's results.
Average growth rate+807.69%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.